Evommune, Inc.
For the period ended Sep 30, 2025. Filed Dec 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Dec 11, 2025
EVMN$7.84+2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit (unaudited)
(In thousands, except share amounts)
| For the Nine Months Ended September 30, 2025 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Preferred stock · Common stock · Additionalpaid-in · Accumulated | ||||||||||||
| Shares · Amount · Shares · Amount · capital · Deficit · Total | ||||||||||||
| Balance, January 1, 2025 | 116,716,142 | $ | 191,776 | 1,551,420 | $ | — | $ | 7,982 | $ | (152,219) | $ | (144,237) |
| Issuance of common stock on exercise of options | — | — | 3,545 | — | 6 | — | 6 | |||||
| Issuance of Series C convertible preferred stock, net of transaction costs | 40,941,587 | 65,228 | — | — | — | — | — | |||||
| Stock-based compensation | — | — | — | — | 1,660 | — | 1,660 | |||||
| Vesting of early exercised options | — | — | — | — | 31 | — | 31 | |||||
| Net loss | — | — | — | — | — | (40,597) | (40,597) | |||||
| Balance, September 30, 2025 | 157,657,729 | $ | 257,004 | 1,554,965 | $ | — | $ | 9,679 | $ | (192,816) | $ | (183,137) |
| For the Nine Months Ended September 30, 2024 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Preferred stock · Common stock · Additionalpaid-in · Accumulated | ||||||||||||
| Shares · Amount · Shares · Amount · capital · Deficit · Total | ||||||||||||
| Balance, January 1, 2024 | 85,222,619 | $ | 149,374 | 1,545,137 | $ | — | $ | 6,197 | $ | (83,911) | $ | (77,714) |
| Issuance of common stock on exercise of options | — | — | 652 | — | 2 | — | 2 | |||||
| Stock-based compensation | — | — | — | — | 1,228 | — | 1,228 | |||||
| Vesting of early exercised options | — | — | — | — | 38 | — | 38 | |||||
| Net loss | — | — | — | — | — | (46,082) | (46,082) | |||||
| Balance, September 30, 2024 | 85,222,619 | $ | 149,374 | 1,545,789 | $ | — | $ | 7,465 | $ | (129,993) | $ | (122,528) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.